The perioperative effect of ERAS protocol in patients with lung cancer: a randomized controlled study Authors: Duan Xiao, Peng Deng, Zhihong Feng, Chi Yao, Bing Yuan Published: 2026 ABSTRACT ObjectiveTo Explore the Safety and Feasibility of the Enhanced Recovery After Surgery (ERAS) in the Perioperative Clinical Application for Patients with Lung Cancer.MethodsSixty patients with early-stage lung cancer who underwent uniportal video-assisted thoracoscopic surgery (UVATS) lobectomy at Shifang People’s Hospital were selected and randomly divided into the ERAS group (E group) and the control group (C group). The differences in postoperative recovery and the incidence of complications between the two groups were compared.ResultsThe postoperative pain score of patients in E group was lower than that in C group (P < 0.05). Postoperatively, the levels of high-sensitivity C-reactive protein (hs-CRP), white blood cell count (WBC), and percentage of neutrophils (NEUT%) in E group were lower than those in C group (P < 0.05); the time to first ambulation after surgery, duration of drainage, length of hospital stay, and total hospitalization cost in E group were all less than those in C group (P < 0.05). Patient satisfaction in E group was higher (P < 0.05). The incidence of complications in E group was lower than that in C group, showing a trend toward reduction without reaching statistical significance (P > 0.05). No 14-day unplanned readmission or reoperation was found in both groups, and the postoperative quality of life in E group was better (P < 0.05).ConclusionLung cancer patients who undergo UVATS lobectomy and receive perioperative ERAS achieve faster recovery and higher satisfaction.Trial registrationThe study was registered in the Chinese Clinical Trial Registry (ChiCTR2500111029) on 23/10/2025. Introduction The concept of Enhanced Recovery After Surgery (ERAS) was first proposed by Danish surgeon Kehlet in 1997. Its core lies in implementing proactive interventions throughout the perioperative period, by which various processes are optimized to relieve patients’ surgical trauma and pain and accelerate their rehabilitation [1]. In 2001, a European surgical academic group formulated protocols and guidelines for enhanced postoperative recovery and established an ERAS research group, which emphasized that ERAS should focus on the quality of postoperative recovery and guide its development toward a more systematic and standardized direction [2]. Subsequently, the concept of ERAS has been continuously expanded and gradually applied in multiple surgical fields, laying a solid foundation for the development of ERAS in China [3, 4]. Thoracic surgery has undergone two major advancements: one is the switch from open surgery to minimally invasive surgery, and the other is the use of structured clinical pathways based on ERAS guidelines [5]. At present, non-small cell lung cancer (NSCLC) remains the most common type of lung cancer, accounting for more than 80% of all lung cancer cases. For patients with stage I, stage II, and some cases of stage III NSCLC, video-assisted thoracoscopic surgery (VATS) remains the first-choice treatment [6]. Since the advent of thoracoscopic surgery, it has gone through the development stage of traditional three-port VATS in China. With the continuous introduction of new operational instruments and optical imaging technologies, as well as thoracic surgeons’ constant pursuit of the concept of minimally invasive surgery, uniportal video-assisted thoracoscopic surgery (UVATS) has emerged as the times require [7]. In 2011, Gonzalez [8] performed the world’s first UVATS for lung cancer. In 2015, Xie et al. in China reported 1063 cases of patients who underwent UVATS and confirmed the surgery’s safety and feasibility [9]. UVATS boasts prominent advantages such as small surgical incisions, good cosmetic results, and significantly reduced postoperative pain. It can be regarded as a revolutionary and ultimate manifestation of minimally invasive surgery, which is fully in line with the concept of ERAS [10]. This study aims to investigate the perioperative effects of ERAS versus conventional management in patients with early-stage lung cancer, which can provide a theoretical foundation for the application of ERAS in thoracic surgery. Methods and materials Study design Inclusion criteria: ① Clinically and pathologically staged as Stage Ⅰ; ② Meeting the diagnostic criteria for NSCLC based on pathological and imaging examinations (in accordance with the China Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2015 Edition)); [11] ③ Diagnosed with a single lesion, with the diameter of the lesion ≤ 2.0 cm; ④ No preoperative chemotherapy received; ⑤ Meeting the surgical criteria for single-incision thoracoscopic lobectomy; ⑥ Normal consciousness; ⑦ Consenting to participate in this study. Exclusion criteria: ① Patients with clinical and pathological stage > Stage Ⅰ; ② Patients with disturbance of consciousness; ③ Patients who have received radiotherapy or chemotherapy; ④ Patients who do not meet the surgical criteria for single-incision thoracoscopic lobectomy; ⑤ Patients with a previous history of malignant tumors; ⑥ Patients who refuse to participate in this study. All patients in both groups underwent standard anatomical lobectomy via UVATS. The surgical approach was uniformly selected based on tumor location, preoperative chest CT findings, lesion size ≤ 2.0 cm, clinical stage I, and standardized minimally invasive oncologic principles in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2015 Edition). All operations were performed by the same experienced thoracic surgical team to ensure consistent surgical quality. Randomization and blinding This study was designed as a single-center, randomized, single-blind controlled trial. Participants will be randomly assigned to the ERAS group (E group) and the control group (C group) at a 1:1 ratio. An independent statistician from our hospital, who was not involved in patient enrollment, clinical intervention or outcome assessment of the present study, generated an unrestricted random sequence using SPSS 26.0 statistical software to ensure the randomness and objectivity of the sequence. The aforementioned independent statistician sealed the generated random sequence one by one in opaque, sequentially numbered special sealed envelopes according to numerical order. The sealed envelopes were stored in a locked filing cabinet at the hospital’s Clinical Research Center with access restricted to designated researchers, thus strictly avoiding allocation bias. After eligible patients signed the informed consent form, researchers in charge of patient enrollment opened the envelopes in sequence and determined the patients’ group allocation according to the random sequence inside the envelopes, followed by the implementation of the corresponding perioperative management protocols. Medical staff responsible for patient surgery, anesthesia and perioperative nursing were not involved in any steps of random sequence generation, envelope preparation or group allocation. To ensure protocol compliance, both the researchers and the patients were informed of the treatment group assignments. This study adopted a single-blind design only for the statisticians responsible for data collection and analysis, who were kept unaware of the group allocation throughout the research process. Interventions The E group received a comprehensive and step-by-step ERAS perioperative management protocol, while the C group was treated with conventional perioperative management procedures. The detailed protocols of the two groups are described as follows, and a concise comparison summary is presented in Table 1. E group (ERAS protocol) Preoperative health education and psychological intervention: Health education on ERAS measures was initiated for patients upon admission, including preoperative smoking cessation, respiratory function training, a nutritious diet, and the benefits of early postoperative ambulation and oral feeding.Patients, especially those with significant concerns about surgery and prognosis, were actively communicated with to alleviate their psychological burden by providing relevant surgical information. Patients were informed preoperatively of the surgical approach, incision size, and the purpose of postoperative thoracic tube indwelling, with emphasis on the advantages of UVATS.Preoperative respiratory function training and physical exercise were performed, such as using a spirometer or blowing balloons. Appropriate nutritional support was administered to patients with malnutrition.Clear fluids were allowed up to 2–4 h before anesthesia induction. Preoperative carbohydrate loading was performed with 10% glucose solution (200 mL) orally 2 h before anesthesia induction in non-diabetic patients. For patients with diabetes mellitus, 5% glucose solution (100–200 mL) was used with perioperative blood glucose monitoring to ensure safety. Prophylactic intravenous antibiotics were administered 30 min before surgery.During intraoperative disinfection, patient warmth was maintained. Anesthesia was a combination of ultrasound-guided nerve block and general anesthesia. Ultrasound-guided paravertebral nerve block was performed at the T5 level using 0.33% ropivacaine 30 mL under real-time ultrasound in-plane guidance. General anesthesia was performed with anesthetics with a short half-life. An incision protector was used to safeguard the surgical incision, and gentle manipulation was adopted to avoid excessive traction and compression of lung tissue.Restrictive fluid infusion was implemented intraoperatively, with vasoactive drugs administered to elevate blood pressure, and the total intraoperative fluid infusion volume was less than 1000 ml. A single thoracic drainage tube was placed and led out through the incision.On the day after surgery, patients were guided to sit up in bed 2–3 times, during which they were encouraged to actively move their lower limbs or receive massage on the lower limb muscle groups from family members; this series of interventions, combined with pneumatic compression pump therapy, was applied to assist in preventing deep vein thrombosis.At 6 h postoperatively, oral water and liquid food were permitted, and the urinary catheter was removed. On the first postoperative day, patients were encouraged to ambulate 4–6 times for approximately 10 min each time, after which the ambulation duration was extended on the second postoperative day.Patient-controlled analgesia (PCA) pumps were used for analgesia, with which patients were encouraged to cough and expectorate sputum effectively.A single tube was used for the patients in the E group, and the chest tube was removed when the following conditions were met: (1) no progressive bleeding or chylothorax; (2) no persistent air leakage during continuous cough; (3) No segmental or lobar collapse on chest imaging, and no decreased breath sounds or tracheal deviation on physical examination; (4) daily serous effusion less than 300 ml/24 h, with the highest volume not exceeding 450 ml/24 h [12].The total daily intravenous fluid infusion volume was controlled to less than 800 ml postoperatively. Preoperative health education and psychological intervention: Health education on ERAS measures was initiated for patients upon admission, including preoperative smoking cessation, respiratory function training, a nutritious diet, and the benefits of early postoperative ambulation and oral feeding. Preoperative health education and psychological intervention: Health education on ERAS measures was initiated for patients upon admission, including preoperative smoking cessation, respiratory function training, a nutritious diet, and the benefits of early postoperative ambulation and oral feeding. Patients, especially those with significant concerns about surgery and prognosis, were actively communicated with to alleviate their psychological burden by providing relevant surgical information. Patients were informed preoperatively of the surgical approach, incision size, and the purpose of postoperative thoracic tube indwelling, with emphasis on the advantages of UVATS. Patients, especially those with significant concerns about surgery and prognosis, were actively communicated with to alleviate their psychological burden by providing relevant surgical information. Patients were informed preoperatively of the surgical approach, incision size, and the purpose of postoperative thoracic tube indwelling, with emphasis on the advantages of UVATS. Preoperative respiratory function training and physical exercise were performed, such as using a spirometer or blowing balloons. Appropriate nutritional support was administered to patients with malnutrition. Preoperative respiratory function training and physical exercise were performed, such as using a spirometer or blowing balloons. Appropriate nutritional support was administered to patients with malnutrition. Clear fluids were allowed up to 2–4 h before anesthesia induction. Preoperative carbohydrate loading was performed with 10% glucose solution (200 mL) orally 2 h before anesthesia induction in non-diabetic patients. For patients with diabetes mellitus, 5% glucose solution (100–200 mL) was used with perioperative blood glucose monitoring to ensure safety. Prophylactic intravenous antibiotics were administered 30 min before surgery. Clear fluids were allowed up to 2–4 h before anesthesia induction. Preoperative carbohydrate loading was performed with 10% glucose solution (200 mL) orally 2 h before anesthesia induction in non-diabetic patients. For patients with diabetes mellitus, 5% glucose solution (100–200 mL) was used with perioperative blood glucose monitoring to ensure safety. Prophylactic intravenous antibiotics were administered 30 min before surgery. During intraoperative disinfection, patient warmth was maintained. Anesthesia was a combination of ultrasound-guided nerve block and general anesthesia. Ultrasound-guided paravertebral nerve block was performed at the T5 level using 0.33% ropivacaine 30 mL under real-time ultrasound in-plane guidance. General anesthesia was performed with anesthetics with a short half-life. An incision protector was used to safeguard the surgical incision, and gentle manipulation was adopted to avoid excessive traction and compression of lung tissue. During intraoperative disinfection, patient warmth was maintained. Anesthesia was a combination of ultrasound-guided nerve block and general anesthesia. Ultrasound-guided paravertebral nerve block was performed at the T5 level using 0.33% ropivacaine 30 mL under real-time ultrasound in-plane guidance. General anesthesia was performed with anesthetics with a short half-life. An incision protector was used to safeguard the surgical incision, and gentle manipulation was adopted to avoid excessive traction and compression of lung tissue. Restrictive fluid infusion was implemented intraoperatively, with vasoactive drugs administered to elevate blood pressure, and the total intraoperative fluid infusion volume was less than 1000 ml. A single thoracic drainage tube was placed and led out through the incision. Restrictive fluid infusion was implemented intraoperatively, with vasoactive drugs administered to elevate blood pressure, and the total intraoperative fluid infusion volume was less than 1000 ml. A single thoracic drainage tube was placed and led out through the incision. On the day after surgery, patients were guided to sit up in bed 2–3 times, during which they were encouraged to actively move their lower limbs or receive massage on the lower limb muscle groups from family members; this series of interventions, combined with pneumatic compression pump therapy, was applied to assist in preventing deep vein thrombosis. On the day after surgery, patients were guided to sit up in bed 2–3 times, during which they were encouraged to actively move their lower limbs or receive massage on the lower limb muscle groups from family members; this series of interventions, combined with pneumatic compression pump therapy, was applied to assist in preventing deep vein thrombosis. At 6 h postoperatively, oral water and liquid food were permitted, and the urinary catheter was removed. On the first postoperative day, patients were encouraged to ambulate 4–6 times for approximately 10 min each time, after which the ambulation duration was extended on the second postoperative day. At 6 h postoperatively, oral water and liquid food were permitted, and the urinary catheter was removed. On the first postoperative day, patients were encouraged to ambulate 4–6 times for approximately 10 min each time, after which the ambulation duration was extended on the second postoperative day. Patient-controlled analgesia (PCA) pumps were used for analgesia, with which patients were encouraged to cough and expectorate sputum effectively. Patient-controlled analgesia (PCA) pumps were used for analgesia, with which patients were encouraged to cough and expectorate sputum effectively. A single tube was used for the patients in the E group, and the chest tube was removed when the following conditions were met: (1) no progressive bleeding or chylothorax; (2) no persistent air leakage during continuous cough; (3) No segmental or lobar collapse on chest imaging, and no decreased breath sounds or tracheal deviation on physical examination; (4) daily serous effusion less than 300 ml/24 h, with the highest volume not exceeding 450 ml/24 h [12]. A single tube was used for the patients in the E group, and the chest tube was removed when the following conditions were met: (1) no progressive bleeding or chylothorax; (2) no persistent air leakage during continuous cough; (3) No segmental or lobar collapse on chest imaging, and no decreased breath sounds or tracheal deviation on physical examination; (4) daily serous effusion less than 300 ml/24 h, with the highest volume not exceeding 450 ml/24 h [12]. The total daily intravenous fluid infusion volume was controlled to less than 800 ml postoperatively. The total daily intravenous fluid infusion volume was controlled to less than 800 ml postoperatively. C group (conventional management protocol) For C Group, conventional perioperative management protocols were implemented for UVATS lobectomy, with the specific measures as follows: (1) No systematic pulmonary function training was administered to patients preoperatively; (2) Sedative drugs were given to patients preoperatively for anxiety relief; (3) Patients were required to fast from solid food for at least 8 h and from oral fluids for 6 h preoperatively; (4) Urinary catheters were routinely indwelled and removed on the second postoperative day; (5) Patients were instructed to maintain a complete supine position for 6 h postoperatively; (6) Fasting and fluid deprivation were maintained for 24 h postoperatively; (7) Ambulation was permitted no earlier than 24 h after surgery; (8) Thoracic drainage tubes were removed when the maximum drainage volume was no more than 100 ml per 24 h; (9) Opioid drugs were the most commonly used agents in the analgesic regimen for this group. Table 1Perioperative protocols using the enhanced recovery after surgery protocol and conventional treatmentProjectE groupC groupPerioperative projects: Preoperative health educationYesNo Training of cardiopulmonary functionYesNo Prophylactic antithrombotic treatmentYesYes All-purpose foodYesNo, fasting Prophylactic use of antibioticsYesYesIntraoperative projects: Maintain anesthesia under EEG dual-spectrum monitoringYesYes Ultrasound guided paraspinal nerve blockYesNo Ropivacaine infiltration of surgical incisionsYesYes Placement of thoracic drainage tubeYesYes Intraoperative body temperature condition monitoringYesYes Intraoperative fluid managementYesYesPostoperative projects: Early activityYesNo Early removal of thoracic drainage tubeYesNo Early feedingYesNo Postoperative rewarmingYesYes Preventing nausea and emesisYesYes Postoperative respiratory managementYesYes Patient Controlled intravenous analgesiaYesYes, if the patient asks Wound managementYesNo Prophylactic antithrombotic treatmentYesYes Postoperative health educationYesNo Table 1Perioperative protocols using the enhanced recovery after surgery protocol and conventional treatmentProjectE groupC groupPerioperative projects: Preoperative health educationYesNo Training of cardiopulmonary functionYesNo Prophylactic antithrombotic treatmentYesYes All-purpose foodYesNo, fasting Prophylactic use of antibioticsYesYesIntraoperative projects: Maintain anesthesia under EEG dual-spectrum monitoringYesYes Ultrasound guided paraspinal nerve blockYesNo Ropivacaine infiltration of surgical incisionsYesYes Placement of thoracic drainage tubeYesYes Intraoperative body temperature condition monitoringYesYes Intraoperative fluid managementYesYesPostoperative projects: Early activityYesNo Early removal of thoracic drainage tubeYesNo Early feedingYesNo Postoperative rewarmingYesYes Preventing nausea and emesisYesYes Postoperative respiratory managementYesYes Patient Controlled intravenous analgesiaYesYes, if the patient asks Wound managementYesNo Prophylactic antithrombotic treatmentYesYes Postoperative health educationYesNo Perioperative protocols using the enhanced recovery after surgery protocol and conventional treatment Outcome measures Primary outcome: Postoperative pain score after surgery measured by Visual Analogue Scale (VAS). Secondary outcomes: Levels of high-sensitivity C-reactive protein (hs-CRP), white blood cell count (WBC), and neutrophil percentage (NEUT%); time to first ambulation; duration of chest tube drainage; length of hospital stay; total hospitalization cost; patient satisfaction score; postoperative quality of life (QoL); incidence of postoperative complications; 14-day unplanned readmission and reoperation rates. (1) General Materials: all patients’ basic information (gender, age, Body Mass Index (BMI), etc.), operation time, intraoperative blood loss, number of lymph node stations and total nodes dissected, time to first ambulation after surgery, postoperative hospital stay, and total hospitalization cost were recorded. (2) Postoperative Pain Assessment: All patients underwent pain assessment using the VAS. The VAS scoring criteria are as follows: a score of 0 indicates no pain; scores of 1–3 indicate mild pain that is tolerable; scores of 4–6 indicate moderate pain that is barely tolerable; and scores of 7–10 indicate severe pain that is unbearable. Based on the pain scale and patients’ subjective feelings, the maximum pain score was recorded at 6 h (T1), 12 h (T2), 24 h (T3), 48 h (T4), and 72 h (T5) after surgery, respectively. (3) Inflammatory Markers: all patients underwent blood tests before surgery (T0), on the 1st day after surgery (T1), and on the 3rd day after surgery (T2). Indicators including hs-CRP, WBC, and NEUT% were monitored. (4) Clinical indicators including the time to first ambulation after surgery, duration of drainage (defined as the total duration in days from surgery to removal), postoperative hospital stay, total hospitalization cost, and patient satisfaction were recorded. (5) The incidence of postoperative complications was recorded, including pulmonary infection, pleural effusion, persistent air leakage, incision infection, and arrhythmia. A composite endpoint of any postoperative complication was defined for statistical analysis, which served as the sole efficacy index for complication assessment in this study. All postoperative complications were graded by the Clavien-Dindo Classification (Version 5.0) [13]: Grade Ⅰ: Mild, symptomatic treatment only; Grade Ⅱ: Requiring intravenous pharmacotherapy; Grade Ⅲ: Needing surgical/endoscopic/radiological intervention; Grade Ⅳ: Life-threatening, ICU admission required; Grade Ⅴ: Death from complications. (6) Short-term ERAS-related outcomes: 14-day unplanned readmission rate, 14-day reoperation rate, and postoperative QoL assessed by the EORTC QLQ-C30 at 7 days post-surgery were recorded [14]. Statistical analysis The prespecified primary outcome was the VAS pain score at 6 h postoperatively (T1). T1 was chosen because it reflects the early peak pain period and is most sensitive to analgesic effects. Sample size calculation was based on our pilot study (n = 10), which showed a clinically relevant between-group difference in T1 VAS (Cohen’s d = 0.7717, large effect size) but did not reach statistical significance (P = 0.102) due to the small pilot sample. Set α = 0.05 and power = 0.8 was used to determine the study. According to the formula estimate the effective sample size N ≈ 26 for each group. Invasive clinical trials often need to recruit more subjects to prevent patients from falling out during follow-up. Based on experience, it is assumed that 10% of the trials are lost to follow-up, so each group of samples is adjusted up to N*=N÷(1-0.1) ≈ 29. Data analysis was achieved by using SPSS for Windows version 26.0. Normally distributed measurement data were expressed as mean ± standard deviation(‾x ± s). Continuous variables that were normally distributed were analyzed using an independent t-test, while non-normally distributed variables were analyzed using the Mann–Whitney U test for comparison between the groups. Repeated measures analysis of variance will be used for intra-group comparisons. The χ2 test will be used for the comparison of count data. Given the extremely low event rates of individual postoperative complications, no statistical tests were conducted for single complication types, and only descriptive statistics (case number and percentage) were reported. Statistical comparison was solely performed for the composite endpoint of any postoperative complication using the χ² test. P < 0.05, indicating that the difference is statistically significant. Results Participants A total of 64 early stage lung cancer patients who were scheduled for single port thoracoscopic lobectomy of the lung at Shifang people’s Hospital were enrolled in this study from October 2025 to April 2026. After 4 refused to participate, 60 eligible participants were included in the final analysis. They were randomly divided into E group and C group. (Fig. 1). No protocol deviations were observed throughout the study, and the enhanced recovery after surgery (ERAS) protocol was fully and strictly implemented in all patients allocated to E group in accordance with the predefined study procedures. All randomized patients completed the trial without any loss to follow-up or discontinuation of intervention, ensuring the integrity of the study data. Fig. 1Consort diagram. Initially, 64 patients were randomly assigned to 1 of 2 groups as follows: the ERAS group (E group) or the control group (C group). 60 patients (30 in E group and 30 in C group) completed this study Consort diagram. Initially, 64 patients were randomly assigned to 1 of 2 groups as follows: the ERAS group (E group) or the control group (C group). 60 patients (30 in E group and 30 in C group) completed this study Demographic and perioperative data As shown in Table 2, there were no statistically significant differences in data such as gender, age, BMI value, the pathology of the patients, the type of lung cancer, the pulmonary fucnction test before surgery(FEV1, MVV), the nutritional index(albumin, hemoglobin) and the location of surgery site (all P > 0.05), indicating that the data of the two groups were comparable. There were no significant differences between groups in mean operative time, intraoperative blood loss, or the number of lymph node stations and total nodes dissected (all P > 0.05), confirming comparable surgical extent and consistency between the two groups. Table 2Demographic data in the study groupsIndexE group(n = 30)C group(n = 30)P valueAge (years)62.5 ± 9.3261.2 ± 7.680.558Body mass index(kg/m2)24.27 ± 2.8323.85 ± 2.360.535Gender (Male/Female)16/1414/160.606Duration of surgery (min)116.8 ± 30.04127.39 ± 31.110.185Intraoperative blood loss (mL)32.33 ± 13.5727.33 ± 13.630.16Number of lymph nodes cleared during surgery (pcs)9.2 ± 6.67.67 ± 5.430.331Lymph node stations dissected3.1 ± 0.93.0 ± 0.80.651Pathological type (Adenocarcinoma/Squamous cell carcinoma)22/824/60.542Type of lung cancer (central/peripheral)9/218/220.774Pulmonary functionFEV1(L)2.75 ± 0.62.79 ± 0.720.816MVV(L)94.89 ± 15.0495.59 ± 16.160.863Nutritional indexAlbumin(g/L)41.33 ± 8.1140.87 ± 7.60.821Hemoglobin(g/L)123.43 ± 17.8126.47 ± 15.770.487Location of surgery siteRUL15(50%)14(46.7%)0.796LUL7(23.33%)6(20%)0.754RLL4(13.33%)6(20%)0.488LLL2(6.7%)3(10%)0.64RML2(6.7%)1(3.3%)0.554ComorbidityHypertension11(36.7%)13(43.3%)0.598Diabetes mellitus9(30%)10(33.3%)0.781Heart disease3(10%)5(16.7%)0.448Brain vascular disease2(6.7%)3(10%)0.64COPD11(36.7%)9(30%)0.584Data are mean±standard deviation. FEV1 = forced expiratory volume in 1.0 s. MVV = maximum volume for ventilation. RUL = Right Upper Lobe. LUL = Left Upper Lobe. RLL = Right Lower Lobe. LLL = Left Lower Lobe. RML = Right Middle Lobe. COPD = chronic obstructive pulmonary disease Table 2Demographic data in the study groupsIndexE group(n = 30)C group(n = 30)P valueAge (years)62.5 ± 9.3261.2 ± 7.680.558Body mass index(kg/m2)24.27 ± 2.8323.85 ± 2.360.535Gender (Male/Female)16/1414/160.606Duration of surgery (min)116.8 ± 30.04127.39 ± 31.110.185Intraoperative blood loss (mL)32.33 ± 13.5727.33 ± 13.630.16Number of lymph nodes cleared during surgery (pcs)9.2 ± 6.67.67 ± 5.430.331Lymph node stations dissected3.1 ± 0.93.0 ± 0.80.651Pathological type (Adenocarcinoma/Squamous cell carcinoma)22/824/60.542Type of lung cancer (central/peripheral)9/218/220.774Pulmonary functionFEV1(L)2.75 ± 0.62.79 ± 0.720.816MVV(L)94.89 ± 15.0495.59 ± 16.160.863Nutritional indexAlbumin(g/L)41.33 ± 8.1140.87 ± 7.60.821Hemoglobin(g/L)123.43 ± 17.8126.47 ± 15.770.487Location of surgery siteRUL15(50%)14(46.7%)0.796LUL7(23.33%)6(20%)0.754RLL4(13.33%)6(20%)0.488LLL2(6.7%)3(10%)0.64RML2(6.7%)1(3.3%)0.554ComorbidityHypertension11(36.7%)13(43.3%)0.598Diabetes mellitus9(30%)10(33.3%)0.781Heart disease3(10%)5(16.7%)0.448Brain vascular disease2(6.7%)3(10%)0.64COPD11(36.7%)9(30%)0.584Data are mean±standard deviation. FEV1 = forced expiratory volume in 1.0 s. MVV = maximum volume for ventilation. RUL = Right Upper Lobe. LUL = Left Upper Lobe. RLL = Right Lower Lobe. LLL = Left Lower Lobe. RML = Right Middle Lobe. COPD = chronic obstructive pulmonary disease Demographic data in the study groups Data are mean±standard deviation. FEV1 = forced expiratory volume in 1.0 s. MVV = maximum volume for ventilation. RUL = Right Upper Lobe. LUL = Left Upper Lobe. RLL = Right Lower Lobe. LLL = Left Lower Lobe. RML = Right Middle Lobe. COPD = chronic obstructive pulmonary disease VAS scores As displayed in Fig. 2A, compared to the C group, patients in the E group at T1-T5 showed a decrease in VAS scores (P < 0.05). Fig. 2Variables reflecting the VAS scores and hs-CRP of the two groups at different time points. n = 30 for each group. (A) Visual Analogue Scale; (B) High-sensitivity C-reactive protein. #P < 0.05 vs. baseline; *P < 0.05 vs. control Variables reflecting the VAS scores and hs-CRP of the two groups at different time points. n = 30 for each group. (A) Visual Analogue Scale; (B) High-sensitivity C-reactive protein. #P < 0.05 vs. baseline; *P < 0.05 vs. control The inflammatory reaction index As shown in Figs. 2B and 3, before operation, there was no significant difference in hs-CRP, NEUT%, WBC levels between the two groups (P > 0.05); The hs-CRP, WBC, and NEUT% levels on the first and third day after surgery in both groups were higher than before surgery. The hs-CRP, WBC, and NEUT% levels at these two time points after surgery in E group were lower than those in C group (P < 0.05). Fig. 3Variables reflecting the NEUT% and WBC of the two groups at different time points. n = 30 for each group. (A) Percentage of neutrophils; (B) White blood cell count. #P < 0.05 vs. baseline; *P < 0.05 vs. control Variables reflecting the NEUT% and WBC of the two groups at different time points. n = 30 for each group. (A) Percentage of neutrophils; (B) White blood cell count. #P < 0.05 vs. baseline; *P < 0.05 vs. control Daily chest tube drainage volume As shown in Table 3, in E group, mean drainage on removal day = 215.6 ± 82.3 ml. In C group, tubes were removed later (mean 2.83 days), with removal only when drainage ≤ 100 ml/day (mean 64.2 ± 35.3 ml on removal day). No chylothorax, massive bleeding, or re-intervention for drainage-related complications occurred in either group. Table 3Daily chest tube drainage volume (ml/day) until removalIndexE group (n = 30)C group (n = 30)P valuePostoperative Day 1 (POD 1)281.5 ± 81.2268.4 ± 76.90.524Postoperative Day 2 (POD 2)228.3 ± 85.7215.6 ± 72.30.537Postoperative Day 3 (POD 3)— (most removed)156.2 ± 58.5—Postoperative Day 4 (POD 4)—72.7 ± 31.4—Drainage volume on the day of removal215.6 ± 82.364.2 ± 35.3< 0.001Duration of drainage (d)2.2 ± 0.582.83 ± 1.290.018Data are mean±standard deviation Table 3Daily chest tube drainage volume (ml/day) until removalIndexE group (n = 30)C group (n = 30)P valuePostoperative Day 1 (POD 1)281.5 ± 81.2268.4 ± 76.90.524Postoperative Day 2 (POD 2)228.3 ± 85.7215.6 ± 72.30.537Postoperative Day 3 (POD 3)— (most removed)156.2 ± 58.5—Postoperative Day 4 (POD 4)—72.7 ± 31.4—Drainage volume on the day of removal215.6 ± 82.364.2 ± 35.3< 0.001Duration of drainage (d)2.2 ± 0.582.83 ± 1.290.018Data are mean±standard deviation Daily chest tube drainage volume (ml/day) until removal Data are mean±standard deviation Postoperative rehabilitation indicators As shown in Table 4, in E group, the time to first ambulation after surgery was earlier than that in C group (P < 0.05). Compared with the C group, E group had shorter postoperative duration of indwelling tubes, shorter postoperative hospital stay, lower total hospitalization cost, and higher patient satisfaction (all P < 0.05). No unplanned readmission or reoperation occurred in either group within 14 days post-surgery (0% for both groups). The postoperative QoL score of E group was higher than that of C group (P < 0.05). Table 4Postoperative rehabilitation statusIndexE group(n = 30)C group(n = 30)P valueThe time to first ambulation after surgery (h)13.43 ± 4.1716 ± 3.430.017Hospitalization time (d)8.73 ± 3.7711.07 ± 2.830.009Hospitalization expenses (yuan)27108.97 ± 7471.5131277.32 ± 5957.420.02Patient satisfaction (score)87.34 ± 13.9876.25 ± 11.790.002QoL (score)56.34 ± 5.9353.45 ± 4.880.044Data are mean±standard deviation. QoL = quality of life Table 4Postoperative rehabilitation statusIndexE group(n = 30)C group(n = 30)P valueThe time to first ambulation after surgery (h)13.43 ± 4.1716 ± 3.430.017Hospitalization time (d)8.73 ± 3.7711.07 ± 2.830.009Hospitalization expenses (yuan)27108.97 ± 7471.5131277.32 ± 5957.420.02Patient satisfaction (score)87.34 ± 13.9876.25 ± 11.790.002QoL (score)56.34 ± 5.9353.45 ± 4.880.044Data are mean±standard deviation. QoL = quality of life Postoperative rehabilitation status Data are mean±standard deviation. QoL = quality of life Complications As shown in Table 5, the incidence of individual postoperative complications was presented as descriptive statistics for both groups due to the low event rates, and a composite endpoint of any postoperative complication was established for statistical comparison. Postoperative complications were analyzed by predefined definitions and Clavien-Dindo grading (no Grade Ⅳ/Ⅴ occurred). The overall incidence of any complication (Grade Ⅰ-Ⅲ) was 16.67% (5/30) in E group and 36.67% (11/30) in C group. Although the E group showed a trend toward lower complication incidence, the difference did not reach statistical significance (P > 0.05). Table 5Complications occurrenceIndexE group(n = 30)C group(n = 30)P valueClavien-Dindo GradeIncision infection n(%)2(6.67%)3(10%)-ⅠArrhythmia n(%)1(3.33%)1(3.33%)-ⅡPulmonary infection n(%)1(3.33%)2(6.67%)-ⅡPleural effusion n(%)03(10%)-ⅢChest leakage n(%)1(3.33%)2(6.67%)-ⅡComplication (Grade Ⅰ-Ⅲ) n(%)5(16.67%)11(36.67%)0.08- Table 5Complications occurrenceIndexE group(n = 30)C group(n = 30)P valueClavien-Dindo GradeIncision infection n(%)2(6.67%)3(10%)-ⅠArrhythmia n(%)1(3.33%)1(3.33%)-ⅡPulmonary infection n(%)1(3.33%)2(6.67%)-ⅡPleural effusion n(%)03(10%)-ⅢChest leakage n(%)1(3.33%)2(6.67%)-ⅡComplication (Grade Ⅰ-Ⅲ) n(%)5(16.67%)11(36.67%)0.08- Complications occurrence Discussion Postoperative analgesia, as a key component of ERAS, is a core measure to achieve its ultimate goal, which directly influences patients’ early ambulation, organ function recovery and length of hospital stay [15]. In this study, patients in E group were managed with a multimodal analgesia (MMA) protocol, which included preoperative ultrasound-guided paravertebral nerve block, postoperative patient-controlled analgesia (PCA) pump use, and infusion of analgesic drugs such as parecoxib sodium [16, 17]. The significantly lower postoperative VAS scores in E group compared with C group demonstrated that MMA management could markedly alleviate postoperative pain, which was consistent with the previous findings of our research group [18] In addition, the VAS scores of patients in both groups showed an upward trend before T3. This may be attributed to the limited duration of action of ropivacaine used in paravertebral block or incision block. The VAS scores of T4 and T5 in E group showed a decreasing trend, and the difference from C group increased. This may be because patients in E group had their thoracic drainage tubes removed earlier after surgery, which alleviated the pain caused by the friction between the tubes and the chest wall. Postoperative inflammatory markers, including hs−CRP, WBC and NEUT%, are important laboratory parameters that evaluate the inflammatory response and infection risk after surgical trauma, and their combined analysis can improve diagnostic sensitivity and specificity [19]. The significantly lower levels of these inflammatory indicators in E group may be associated with the combined effects of the multimodal interventions in our ERAS bundle, which might contribute to attenuating systemic surgical stress and neuroendocrine inflammatory responses induced by UVATS lobectomy. Firstly, preoperative carbohydrate loading in E group may modulate perioperative metabolism, might avoid insulin resistance and catabolic stress caused by prolonged fasting, and thus may reduce the basal level of inflammatory mediator release [20]. Secondly, by reducing tissue edema and pulmonary interstitial fluid accumulation, intraoperative restrictive fluid management (total infusion < 1000 ml) may alleviate local inflammatory infiltration and systemic inflammatory response caused by tissue hypoperfusion and reoxygenation injury [21]. Thirdly, early postoperative ambulation and oral feeding (initiated at 6 h postoperatively) in E group may promote gastrointestinal peristalsis and systemic circulation recovery, improve immune cell function, and prevent the excessive inflammatory response caused by prolonged bed rest and intestinal mucosal barrier dysfunction [22]. Notably, ultrasound−guided paravertebral nerve block (PVB), which was applied only in E group, may independently contribute to reducing systemic inflammation, beyond the effects of early feeding and early ambulation. By blocking nociceptive afferent signals from the thoracic wall and pleura, PVB may suppress the activation of the hypothalamic−pituitary−adrenal axis and sympathetic nervous system, thereby possibly reducing the release of proinflammatory cytokines such as TNF−α and IL−6 [23]. This neural−immune modulation may reduce hepatic synthesis of hs−CRP and peripheral leukocyte activation, leading to lower postoperative WBC and NEUT% levels [24]. This helps clarify that the reduced inflammatory response was not solely due to early oral feeding or mobilization, but was driven significantly by the multimodal analgesia component of PVB. Additionally, our data on ERAS-related inflammation reduction were consistent with the thoracic surgery ERAS evidence in both studies, confirming the reproducibility of ERAS benefits in minimally invasive lung cancer surgery [25, 26]. Future factorial design studies are warranted to clarify the independent contribution of each individual ERAS component. From a dialectical perspective, the significant biological reduction in hs−CRP, WBC, and NEUT% in E group indicates effective attenuation of surgical stress and systemic inflammation. However, this biological improvement did not translate into a statistically significant reduction in clinical events such as pulmonary infection (1 case vs. 2 cases). This discrepancy may be explained by the extremely low overall incidence of postoperative pneumonia in both groups, as well as the limited sample size, which resulted in insufficient statistical power to detect between−group differences. Therefore, the lower inflammatory markers reflect a favorable biological effect of ERAS, while confirmation of corresponding clinical benefits in reducing infectious complications requires larger−sample studies Prolonged placement of thoracic drainage tubes increases the risk of infection, which may even lead to sepsis in patients with compromised immunity due to chronic diseases or prolonged bed rest [27].Postoperative discomfort such as chest pain or tightness, which may stem from drainage tube irritation or pleurisy, can coincide with lung tissue damage during drainage that leads to pneumothorax or hemothorax [28]. Removal of the drainage tube allows earlier mobilization, which shortens hospital stay, lowers medical costs, and prevents complications such as deep vein thrombosis and atelectasis caused by restricted mobility [29]. Yi et al. [25]. emphasized individualized early chest tube removal as a key ERAS measure for lung cancer surgery, and our results validated this by showing a 0.63-day shorter drainage duration in E group without increased complications, supplementing its scarce quantitative evidence for uniportal thoracoscopic lobectomy. Additionally, our findings align with the meta-analysis by Li et al. [30]., which demonstrated that ERAS shortens hospital stay for lung cancer surgery by 2.0-2.5 days; in our study, ERAS reduced hospitalization by 2.34 days, consistent with this core conclusion. The lower total hospitalization cost in E group was mainly due to shorter postoperative hospital stay. Additional savings came from reduced use of intravenous fluids, drainage materials, and analgesic medications, as well as fewer postoperative complications and lower related treatment costs (including antibiotics, aerosol inhalation, wound care, thoracic puncture, and prolonged drainage management). Notably, no 14-day readmission or reoperation was observed in either group, and ERAS further improved postoperative QoL, which confirmed the short-term safety and efficacy of ERAS in UVATS lobectomy. Various complications may occur after UVATS lobectomy, such as postoperative pulmonary infection, surgical site infection, pleural effusion, persistent air leakage, and arrhythmia. These complications cause varying degrees of harm to patients. Individual postoperative complications were associated with low event rates, making statistical comparisons of single complications meaningless; thus, only descriptive statistics were presented for these outcomes, and a composite endpoint of any postoperative complication was further defined for exploratory analysis. Although E group showed a trend toward reduced overall complication incidence compared with C group, the difference did not reach statistical significance, which should be interpreted with caution as the present study was not powered to detect differences in complication outcomes. Larger, multicenter randomized controlled trials are warranted to validate the potential protective effect of ERAS on postoperative complications in patients undergoing UVATS lobectomy. This study has several limitations. First, it was a single-center trial with a small sample size (30 patients per group), which limits the generalizability of the findings and reduces statistical power for analyzing postoperative complication rates, leading to no significant statistical difference in complication incidence despite numerical reduction in E group. Second, the single-blind design (only statisticians blinded) may introduce performance and detection bias, especially for patient-reported outcomes such as VAS scores and satisfaction. Subjective positive bias in the ERAS group may have contributed to lower pain scores and higher satisfaction, which should be considered when interpreting the results. Third, the hospitalization cost analysis was only from a hospital perspective, and a comprehensive cost-effectiveness analysis would require incorporating indirect costs (e.g., patient productivity loss) with more rigorous methodology. In conclusion, perioperative ERAS management for patients undergoing uniportal thoracoscopic lobectomy for early-stage lung cancer accelerates postoperative recovery, reduces pain and medical costs, and improves patient satisfaction without increasing complication risks, making it worthy of clinical promotion. Based on our findings, clinicians may adopt criteria-based early chest tube removal (daily drainage < 300 ml/24 h, no progressive bleeding or persistent air leakage) as part of thoracic ERAS protocols. Additionally, implementing ultrasound-guided paravertebral nerve block for multimodal analgesia is recommended to relieve postoperative pain and facilitate early ambulation and oral feeding.